Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: A Phase 2 Study of PF-04449913 for the Treatment of Acute Leukemia Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse

 


A Phase 2 Study of PF-04449913 for the Treatment of Acute Leukemia Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse


Trial Focus

Leukemia/Myelodysplasia

Objective

         This is a clinical trial of investigational drug PF-04449913 which will be administered orally.

IRB Protocol #

12-1558

Trial Status

OPEN

Principle Investigator

DAN POLLYEA

Sponsor

Leukemia Lymphoma Society (LLS)

Contact

EMILY DENONCOURT at (303)748-0566 or EMILY.DENONCOURT@UCDENVER.EDU

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period will determine eligibility. The treatment period will consist of 28 day cycles for as long as your doctor determines you are still benefitting from the treatment. The follow- up period will consist of one final visit to the clinic. // Eligibility criteria include but are not limited to 18 years or older with Acute Leukemia and high risk of post-allogeneic stem cell transplantation relapse.Eligibility criteria include but are not limited to 18 years or older with Acute Leukemia and high risk of post-allogeneic stem cell transplantation relapse.